EMBRACE: One Small Story in Lupus—One Giant Challenge in Clinical Trials
Open Access
- 24 June 2022
- journal article
- editorial
- Published by Wiley in ACR Open Rheumatology
- Vol. 4 (9) , 747-752
Abstract
Clinical trials of novel therapeutics in the United States have not been adequately representative of diverse populations, particularly racial and ethnic minorities. The challenges and consequences of underrepresentation in clinical trial recruitment are exemplified by the case of belimumab, a biologic treatment for systemic lupus erythematosus (SLE), a disease that is more prevalent in patients of Black African ancestry and of Hispanic/Latino ethnicity than in other patient populations. Although belimumab was found to be effective in phase 2 and 3 clinical trials in the general population, post hoc analyses of efficacy data in patients of Black African ancestry showed inconsistent results. Consequently, a cautionary statement regarding belimumab use in this population was added to the product label. To alleviate concerns that belimumab may not be safe and effective for patients of Black African ancestry, the Efficacy and Safety of Belimumab in Black Race Patients with SLE (EMBRACE) study was conducted in a post‐marketing commitment to the Food and Drug Administration. The study recruited only patients who self‐identified as being of Black race; its findings led to the removal of the cautionary labeling of belimumab use in patients of Black African ancestry. Our manuscript highlights the critical lessons learned from the successes and failures of the EMBRACE study. It also provides suggestions for overcoming health disparities, highlighting strategies for conducting well‐designed clinical trials to overcome systematic barriers to diversity in recruitment, with a focus on enacting long‐term support to ensure equity in the process, products, and benefits from drug development and clinical trials.Keywords
This publication has 17 references indexed in Scilit:
- Brief Report: Lupus—An Unrecognized Leading Cause of Death in Young Females: A Population‐Based Study Using Nationwide Death Certificates, 2000–2015Arthritis & Rheumatology, 2018
- Lupus community panel proposals for optimising clinical trials: 2018Lupus Science & Medicine, 2018
- The Representation of Gender and Race/Ethnic Groups in Randomized Clinical Trials of Individuals with Systemic Lupus ErythematosusCurrent Rheumatology Reports, 2018
- Clinical trials recruitment planning: A proposed framework from the Clinical Trials Transformation InitiativeContemporary Clinical Trials, 2018
- Discordance of patient and physician health status concerns in systemic lupus erythematosusLupus, 2017
- Master Protocols to Study Multiple Therapies, Multiple Diseases, or BothNew England Journal of Medicine, 2017
- A Systematic Review of Barriers and Facilitators to Minority Research Participation Among African Americans, Latinos, Asian Americans, and Pacific IslandersAmerican Journal of Public Health, 2014
- Diagnostic vertigo: The journey to diagnosis in systemic lupus erythematosusHealth: An Interdisciplinary Journal for the Social Study of Health, Illness and Medicine, 2013
- Employment and work disability in systemic lupus erythematosus: a systematic reviewRheumatology, 2008
- Complex syndromes, ambivalent diagnosis, and existential uncertainty: The case of Systemic Lupus Erythematosus (SLE)Social Science & Medicine, 2007